改良他汀序贯疗法对PCI患者超敏C反应蛋白的影响及安全性研究

目的：探讨他汀序贯疗法对PCI患者超敏C反应蛋白（hsCRP）的影响及安全性。方法：102例PCI患者,随机分为观察组52例（改良他汀序贯疗法）和对照组50例（口服阿托伐他汀20mg/d）。检测PCI时（PCI前24h内）、PCI后30d早晨空腹hsCRP、丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、肌酸激酶（CK））,观察药物不良反应。结果：与对照组比较,观察组血hsCRP水平降低更明显（P〈0.05）,血ALT、AST、CK水平无明显变化,差异无统计学意义（P〉0.05）。结论：改良他汀序贯疗法对降低PCI患者hsCRP水平更明显,并且安全性良好。

Effects on High Sensitivity C-reaction Protein and Safety Study of Modified Statins Sequential Therapy in Patients with Percutaneous Coronary Intervention

[ Abstract] Objective ： To probe the effectiveness on high sensitivity C-reaction protein（hsCRP） and safety of modified statins sequential therapy in patients with percutaneous coronary intervention（PCI）. Methods ： Totally 102 cases who received PC! were divided randomly into observed group（52 cases using modified sequential atorvastatin） and control group（50 cases using atorvastatin, 20 mg, daily）, measuring the serum levels of hsCRP, ALT, AST, and CK within 24 hours before PCI, 30 days after PCI respectively, and observing the drug-side effects. Results ： Comparing to the control group, the serum levels of hsCRP in observed group decreased with statistical significance（P〈0.05）, but the serum levels of AST, ALT, and CK had no change and little side effect, with no statistical significance（P〉0.05）. Conclusion ： Compared with conventional therapy, modified statins sequential therapy can significantly reduce the serum levels of hsCRP with better safety in patients with PCI.